title: Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.
abstract: OBJECTIVE
  To study the toxicity and efficacy of weekly paclitaxel and carboplatin (PC-W) in women with primary ovarian cancer
  
  
  METHODS
  This investigation extended a phase-I dose finding study and was approved by the institutional review boards of all participating institutions. Between 1999 and 2003, women with radically resected ovarian cancer of FIGO stages II B to IV were enrolled at 17 German centres. Patients received weekly paclitaxel at a dose of 100 mg/m2, followed by carboplatin AUC 2. After a first treatment block consisting of six cycles of chemotherapy, patients had a treatment-free interval of 14 days, followed by a second block of six cycles. Treatment was completed by a 28-days break and a final block of six cycles.
  
  
  RESULTS
  Altogether, 129 women with a mean age of 59 +/- standard deviation 11 years entered the study. Most patients (82.9%) had serous papillary carcinoma of FIGO stage III (72.9%) and IV (20.9%). Participants received 1,851 cycles of chemotherapy; averaging 14.3 +/- 4.3 cycles each patient. PC-W produced low rates of peripheral neuropathy (grade 3: 2.3%, 95% confidence interval [CI] 0.5-6.6%), with rapid recovery after 3 months. However, 72 patients had grade III/IV anaemia (55.8%, 95% CI 46.8-64.5%). There were 36 events of grade III/IV leukopenia (27.9%, 95% CI 20.4-36.5%). One patient sustained neutropenic fever. CA-125- and objective response was noted in 73.9% (95% CI 64.7-81.8%) and 55.6% (95% CI 41.4-69.1%) of patients. Median progression free and overall survival was 21 and 43 months, respectively.
  
  
  CONCLUSIONS
  PC-W is feasible; a randomized study is warranted to compare this new regimen with conventional 3-weekly treatment.
authors: Department of Gynaecology and Gynaecologic Oncology, Charité Virchow University Hospital, Augustenburger Platz 1, 13353 Berlin, Germany. Sehouli@aol.com
authors: Jalid
authors: J
authors: Sehouli
authors: Dirk
authors: D
authors: Stengel
authors: Alexander
authors: A
authors: Mustea
authors: Oumar
authors: O
authors: Camara
authors: Elke
authors: E
authors: Keil
authors: Dirk
authors: D
authors: Elling
authors: Peter
authors: P
authors: Ledwon
authors: Bernd
authors: B
authors: Christiansen
authors: Peter
authors: P
authors: Klare
authors: Gerhard
authors: G
authors: Gebauer
authors: Marina
authors: M
authors: Schwarz
authors: Werner
authors: W
authors: Lichtenegger
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D019540:Area Under Curve; D001772:Blood Cell Count; D001830:Body Surface Area; D016190:Carboplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D020258:Neurotoxicity Syndromes / Q000503:physiopathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D012044:Regression Analysis; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D016190:Carboplatin; D017239:Paclitaxel